

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/11554401>

Chronic diarrhea associated with vagal nerve stimulation

Article in *Neurology* · February 2002

DOI: 10.1212/WNL.58.2.330 · Source: PubMed

CITATIONS

20

READS

1,522

2 authors:



Nerses Sanossian

University of Southern California

176 PUBLICATIONS 2,264 CITATIONS

SEE PROFILE



Sheryl R Haut

Albert Einstein College of Medicine

86 PUBLICATIONS 3,301 CITATIONS

SEE PROFILE

References

1. Mayr N, Zeitlhofer J, Deecke L, Fritz E, Ludwig H, Gisslinger H. Neurological function during long-term therapy with recombinant interferon alpha. *J Neuropsychiatry Clin Neurosci* 1999;11:343–348.
2. Meyers CA, Abbruzzese J. Cognitive functioning in cancer patients: effect of previous treatment. *Neurology* 1992;42:434–436.
3. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. *N Engl J Med* 1997;337:223–229.

4. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. *Neurology* 1995;45:947–950.
5. Amato R, Meyers CA, Ellerhorst J, et al. A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma. *Ann Oncol* 1995;6:911–914.
6. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. *Neurology* 1991;41:672–676.
7. Yoshikubo S, Kimura K, Mizuashi K, Kamo S, Maeda K, Kobatake S. A case of chorea-like movement induced during interferon treatment of chronic hepatitis C. *Nippon Naika Gakkai Zasshi* 1997;86:1036–1038.

Chronic diarrhea associated with vagal nerve stimulation

Nerses Sanossian, MD; and Sheryl Haut, MD

Frequent side effects vagus nerve stimulation (VNS) include hoarseness, cough, and throat pain. Although the vagus nerve physiologically regulates gastrointestinal motility, changes in bowel movement frequency are not included as side effects of VNS. We report a patient who developed chronic diarrhea associated with VNS.

Case report. A 35-year-old man had complex partial seizures since age 14, occurring up to six times per month. Multiple medications including phenytoin, carbamazepine, gabapentin, felbamate, and topiramate did not control the seizures. Intracranial EEG monitoring demonstrated both right and left temporal origin seizures, excluding the patient from consideration for resective surgery and leading to referral for VNS.

After an uncomplicated VNS implantation, the stimulator was set at 0.25 mA/30 Hz/500 ms/30-s on/5-min off/magnet 0.50 mA. The patient was discharged the following day with only a sore throat. One week later, he reported two seizures and an increase in bowel movements. At that time, the stimulator intensity was increased to 0.5 mA and the magnet was increased to 0.75 mA.

Three weeks postimplantation, the patient reported no seizures, but had severe diarrhea consisting of four to five loose bowel movements per day, with exacerbation of preexisting hemorrhoids. Because the patient had no previous history of diarrhea, an association with the VNS was considered, but not found in the literature. Two weeks later, the patient continued to have seizures and frequent watery bowel movements. The stimulator intensity was increased to 0.75 mA, magnet 1.00 mA.

Subsequent anemia led us to perform a full gastrointestinal evaluation, which was significant only for hemorrhoids. A colorectal surgeon was consulted. Because the hemorrhoids were thought to be secondary to the diarrhea, the stimulator was turned off, with the magnet kept on to allow for seizure termination. Three days later, there was a reported reduction in bowel frequency to one to two movements per day.

VNS remained turned off and after 1 month, the diarrhea had completely resolved and the hemorrhoids had improved, postponing planned hemorrhoidectomy. A repeated trial of VNS was initiated, set at an intensity of 0.25 mA. No diarrhea occurred at this setting, but as seizures continued, the stimulus intensity was increased to 0.5 mA. After 1 week, the patient had recurrent diarrhea with loose bowel movements in excess of three per day and excessive bleeding from his hemorrhoids. The VNS was again turned off, with an immediate improvement in his symptoms. He has remained without diarrhea and is awaiting surgical removal of the stimulator.

Discussion. Over 80% of vagal nerve fibers are afferent¹ and it is these fibers that are the presumed target of the VNS. Modulation of gastrointestinal motility occurs through afferent and efferent neurons of the autonomic nervous system. The vagus nerve typically carries afferent signals associated with physiologic regulation of digestion, and efferent signals, which provide the major

parasympathetic input to the gastrointestinal system.² One function of the efferent fibers is to modulate gastrointestinal motility through enervation of the intestinal musculature. It is known that diarrhea and constipation are associated with conditions of vagal nerve dysfunction, such as diabetic visceral neuropathy or surgical vagotomy.³ It is therefore conceivable that stimulation of efferent fibers by the VNS may lead to an increase in gut motility and diarrhea.

Experimental stimulation of the vagus nerve at thresholds that excite the population of C-fibers can have the effect of increasing gastric acid secretion and gastric motility.⁴ It has been postulated that the lack of parasympathetic visceral side effects during VNS therapy is a result of sparing of C-fibers because of lower threshold stimulation,⁵ similar to the lack of respiratory or cardiac side effects seen at this threshold.⁴ VNS in humans has not been associated with significant gastrointestinal symptoms, according to currently published data, and analysis of plasma gastrin levels during stimulation showed no significant increase.⁶ However, the direct effect of VNS on gastrointestinal motility in humans has never been studied.

We hypothesize that our patient manifested chronic diarrhea as an idiosyncratic response to VNS. It is unclear why this patient responded to the stimulation with diarrhea. It may be that his preexisting hemorrhoids exaggerated a response that has gone undetected in other patients. It is also possible that variability in the number of efferent vagal fibers, or distribution of C-fibers, exists and impacts on the gastrointestinal response to VNS. We believe that clinicians should be aware of diarrhea as a potential side effect of VNS.

From the Department of Neurology (Drs. Sanossian and Haut) and Comprehensive Epilepsy Management of the Montefiore Medical Center (Dr. Haut), Albert Einstein College of Medicine, Bronx, NY.

Presented in part at the annual meeting of the Clinical Neurophysiology Society; Montreal, Canada; September 22–23, 2000.

Received July 30, 2001. Accepted in final form October 7, 2001.

Address correspondence and reprint requests to Dr. Nerses Sanossian, Department of Neurology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467-2490; e-mail: sanossia@yahoo.com

Copyright © 2002 by AAN Enterprises, Inc.

References

1. Foley JO, DuBois F. Quantitative studies of the vagus nerve in the cat. I. The ratio of sensory and motor fibers. *J Comp Neurol* 1937;67:49–97.
2. Dockray GJ. The brain–gut axis. In: Yamada T, ed. *Textbook of gastroenterology*. Philadelphia: Lippincott Williams & Wilkins, 1999;71–86.
3. Rosa-e-Silva L, Troncon LE, Oliveira RB, Foss MC, Braga FJ, Gallo JL. Rapid distal small bowel transit associated with sympathetic denervation in type I diabetes mellitus. *Gut* 1996;39:748–756.
4. Woodbury DM, Woodbury JW. Effects of vagal stimulation on experimentally induced seizures in rats. *Epilepsia* 1990;31:S7–S19.
5. Henry TR. Anatomical, experimental, and mechanistic investigations. In: Schacter SC, Schmidt D, eds. *Vagus nerve stimulation*. London: Martin Dunitz Ltd, 2001:1–30.
6. Ramsay RE, Uthman BM, Augustinsson LE, et al. Vagus nerve stimulation for treatment of partial seizures. 2. Safety, side effects, and tolerability. *Epilepsia* 1994;35:627–636.